Explore the Agenda
Workshop A
9:00 am Advancing Patient Reported Outcomes (PROs) for Pain: Improving Validity in Patient Data
Traditional pain measures often fail to capture the complexity of patient experiences and can lack standardisation across trials leading to issues with data accuracy, and regulatory alignment. This workshop explores evolving methods for PROs, balancing real-world patient realities with scientific rigor, and leveraging technology that’s developed significantly in the last two decades, to improve data quality.
Workshop Highlights:
- Discover latest strategies to learn methods to improve accuracy in pain reporting through technology that can reduce subjectivity and recall bias
- Focus on aligning PROs and trial endpoints with regulatory expectations
- Evaluate different strategies towards PRO’s with your peers and hear directly from Vertex on their approved framework
- Learn to assess pain in context, and the benefits, rather than average pain scores
12:00 pm Lunch
Workshop B
1:00 pm Nav1.8, Nav1.7, & Kv7 as Combined Targets for Pain: From an Integrated Platform to Discovery & Translation
Nav1.8, Nav1.7, and Kv7, are central to pain signalling and represent promising targets for novel therapeutics. With emerging evidence indicating that concurrent modulation of these channels may produce advanced analgesic effects, offering therapeutic advantages over single-channel blockade. This workshop will explore how integrated in vitro and in vivo approaches, combined with the development of elective compounds, can accelerate progress from discovery to clinical application.
Key Questions Addressed:
- How do Nav1.7, Nav1.8, and Kv7 channels individually and collectively shape pain pathways, and how does combined modulation alter neuronal excitability? Can biomarkers track multichannel engagement in vivo?
- How can integrated in vitro and in vivo platforms improve preclinical translation?
- What safety risks arise from co-modulating sodium and potassium channels, and how can they be mitigated?
- How can hybrid-selective compounds’ challenges be addressed with integrated platform approaches?
- Can these strategies speed the discovery and clinical translation of pain therapeutics?